Advertisement

Picture Berlin Partner Top News CRIPSR Repairs Immune Cells 650x100px
Organisation › Details

Immunic (Group)

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, vidofludimus calcium (IMU-838), a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn’s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor ROR?/ROR?t, is targeted for development in psoriasis, castration-resistant prostate cancer and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. *

 

Period Start 2019-04-12 renamed
Products Industry immuno modulatory compound (IMO)
  Industry 2 MS DRUGS
Persons Person Vitt, Daniel (Immunic 201701– CEO before 4SC 1997–201612 CSO + Co-Founder before Univ Würzburg)
  Person 2 Whaley, Glenn (Immunic 202203– promoted to CFO joined 2019 before Pernix Therapeutics + Alvogen)
     
Region Region Gräfelfing
  Country Germany
  Street 21 Lochhamer Schlag
  City 82166 Gräfelfing
  Tel +49-89-250079460
    Address record changed: 2024-01-05
     
Basic data Employees C: 51 to 100 (2023-01-01)
  Currency USD
  Profit -120,407,000 (2022-12-31)
  Cash 106,745,000 (2022-12-31)
     
    * Document for »About Section«: Immunic, Inc.. (3/16/22). "Press Release: Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer". New York, NY.
     
   
Record changed: 2023-12-30

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Immunic (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x300px




» top